NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00686114,Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer,https://clinicaltrials.gov/study/NCT00686114,,UNKNOWN,This study is multi-center randomized phase III one to evaluate the difference in local-control and survival rate between patients receiving concurrent chemoradiotherapy combined Tarceva or not.,NO,Esophageal Cancer,DRUG: Paclitaxel|DRUG: Cisplatin|DRUG: Tarceva|RADIATION: Radiotherapy|RADIATION: Radiotherapy,"overall survival, failure: death from any cause, five years after enrollment","Progression-free survival, Failure: occurrence of local or regional progression, distant metastases, or death from any cause, five years after enrollment|local-regional control rate, Failure: occurrence of local or regional progression, three years after enrollment|Adverse events, assessed by RTOG Acute Radiation Morbidity Scoring Criteria and RTOG/EORTC Late Radiation Morbidity Scoring Schema, five years after enrollment|Health-related quality of life, assessed by the Functional Assessment of Cancer Therapy-Esophageal (FACT-E), five years after enrollment",,Wenzhou Medical University,,ALL,"ADULT, OLDER_ADULT",PHASE3,344,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,Shixiu - 1,2008-05,2014-12,2014-12,2008-05-29,,2014-04-29,"1st affliated hospital of Wen Zhou Medical college, Wen Zhou, Zhejiang, 325000, China",
